These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 17705040)
1. Glycolitic enzymes are targets of oxidation in aged human frontal cortex and oxidative damage of these proteins is increased in progressive supranuclear palsy. Martínez A; Dalfó E; Muntané G; Ferrer I J Neural Transm (Vienna); 2008; 115(1):59-66. PubMed ID: 17705040 [TBL] [Abstract][Full Text] [Related]
2. Increased oxidation of certain glycolysis and energy metabolism enzymes in the frontal cortex in Lewy body diseases. Gómez A; Ferrer I J Neurosci Res; 2009 Mar; 87(4):1002-13. PubMed ID: 18855937 [TBL] [Abstract][Full Text] [Related]
3. Laminar distribution of the pathological changes in frontal and temporal cortex in 8 patients with progressive supranuclear palsy. Armstrong RA; Cairns NJ Clin Neuropathol; 2009; 28(5):350-7. PubMed ID: 19788050 [TBL] [Abstract][Full Text] [Related]
4. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Ferrer I; Barrachina M; Puig B Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379 [TBL] [Abstract][Full Text] [Related]
5. Delineation of early changes in cases with progressive supranuclear palsy-like pathology. Astrocytes in striatum are primary targets of tau phosphorylation and GFAP oxidation. Santpere G; Ferrer I Brain Pathol; 2009 Apr; 19(2):177-87. PubMed ID: 18462470 [TBL] [Abstract][Full Text] [Related]
6. Type-dependent oxidative damage in frontotemporal lobar degeneration: cortical astrocytes are targets of oxidative damage. Martínez A; Carmona M; Portero-Otin M; Naudí A; Pamplona R; Ferrer I J Neuropathol Exp Neurol; 2008 Dec; 67(12):1122-36. PubMed ID: 19018247 [TBL] [Abstract][Full Text] [Related]
7. Expression patterns of tau mRNA isoforms correlate with susceptible lesions in progressive supranuclear palsy and corticobasal degeneration. Takanashi M; Mori H; Arima K; Mizuno Y; Hattori N Brain Res Mol Brain Res; 2002 Aug; 104(2):210-9. PubMed ID: 12225876 [TBL] [Abstract][Full Text] [Related]
8. 4-repeat tauopathy sharing pathological and biochemical features of corticobasal degeneration and progressive supranuclear palsy. Katsuse O; Iseki E; Arai T; Akiyama H; Togo T; Uchikado H; Kato M; de Silva R; Lees A; Kosaka K Acta Neuropathol; 2003 Sep; 106(3):251-60. PubMed ID: 12802605 [TBL] [Abstract][Full Text] [Related]
9. Morphological and biochemical correlations of abnormal tau filaments in progressive supranuclear palsy. Takahashi M; Weidenheim KM; Dickson DW; Ksiezak-Reding H J Neuropathol Exp Neurol; 2002 Jan; 61(1):33-45. PubMed ID: 11829342 [TBL] [Abstract][Full Text] [Related]
10. Progressive supranuclear palsy with fronto-temporal atrophy and various tau-positive abnormal structures. Li F; Iseki E; Kosaka K; Nishimura T; Akiyama H; Kato M Clin Neuropathol; 1996; 15(6):319-23. PubMed ID: 8937777 [TBL] [Abstract][Full Text] [Related]
11. Individual and regional variations of phospho-tau species in progressive supranuclear palsy. Puig B; Rey MJ; Ferrer I Acta Neuropathol; 2005 Sep; 110(3):261-8. PubMed ID: 15973541 [TBL] [Abstract][Full Text] [Related]
12. Progressive supranuclear palsy presenting with primary progressive aphasia--clinicopathological report of an autopsy case. Mochizuki A; Ueda Y; Komatsuzaki Y; Tsuchiya K; Arai T; Shoji S Acta Neuropathol; 2003 Jun; 105(6):610-4. PubMed ID: 12669238 [TBL] [Abstract][Full Text] [Related]
14. Cortical atrophy differentiates Richardson's syndrome from the parkinsonian form of progressive supranuclear palsy. Schofield EC; Hodges JR; Macdonald V; Cordato NJ; Kril JJ; Halliday GM Mov Disord; 2011 Feb; 26(2):256-63. PubMed ID: 21412832 [TBL] [Abstract][Full Text] [Related]
15. Thalamic hypoperfusion in early stage of progressive supranuclear palsy (Richardson's syndrome): report of an autopsy-confirmed case. Kobayashi Z; Akaza M; Ishihara S; Tomimitsu H; Inadome Y; Arai T; Akiyama H; Shintani S J Neurol Sci; 2013 Dec; 335(1-2):224-7. PubMed ID: 24075472 [TBL] [Abstract][Full Text] [Related]
16. Tau accumulation in astrocytes in progressive supranuclear palsy is a degenerative rather than a reactive process. Togo T; Dickson DW Acta Neuropathol; 2002 Oct; 104(4):398-402. PubMed ID: 12200627 [TBL] [Abstract][Full Text] [Related]
17. Frontal lobe dysfunction in progressive supranuclear palsy: evidence for oxidative stress and mitochondrial impairment. Albers DS; Augood SJ; Park LC; Browne SE; Martin DM; Adamson J; Hutton M; Standaert DG; Vonsattel JP; Gibson GE; Beal MF J Neurochem; 2000 Feb; 74(2):878-81. PubMed ID: 10646541 [TBL] [Abstract][Full Text] [Related]
18. White matter pathology in progressive supranuclear palsy (PSP): a quantitative study of 8 cases. Armstrong RA Clin Neuropathol; 2013; 32(5):399-405. PubMed ID: 23587170 [TBL] [Abstract][Full Text] [Related]
19. Cortical degeneration in progressive supranuclear palsy. A comparison with cortical-basal ganglionic degeneration. Bergeron C; Pollanen MS; Weyer L; Lang AE J Neuropathol Exp Neurol; 1997 Jun; 56(6):726-34. PubMed ID: 9184663 [TBL] [Abstract][Full Text] [Related]
20. [Widespread argentophilic structures in progressive supranuclear palsy--an autopsy case report]. Hanihara T; Kubota H; Amano N; Yamaoka K; Yagishita S No To Shinkei; 1994 May; 46(5):487-92. PubMed ID: 8060688 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]